Pharmaceutical Companies

Emkay predicts strong upside in Ipca Labs shares on India, export growth

Emkay Global initiated coverage of Ipca Labs shares with 'Buy' rating and a share price target of ₹1,700 -- a 19 per cent upside from current levels

Zydus Lifesciences, RK Pharma sign deal for licensing, commercialisation

Zydus Lifesciences Ltd on Wednesday said it has entered into an exclusive licensing and commercialisation agreement with RK Pharma Inc of the US for a new sterile injectable oncology supportive care product for the US market. Under the terms of this agreement, RK Pharma will manufacture and supply the finished product, while Zydus will be responsible for the NDA (new drug application) submission and commercialisation of the product in the US, the company said in a regulatory filing. The product is expected to be filed in 2026 and will provide a formulation that is intended to provide reduced dosing error and enhanced compliance of healthcare professionals, it added. "This partnership reinforces our commitment to delivering high-quality, affordable medicines and improving patient care," Zydus Lifesciences Managing Director Sharvil Patel said. RK Pharma Founder and Executive Chairman Ravishanker Kovi said, "Our collaboration with Zydus, a company with robust regulatory expertise and

A deadly dose of neglect: Bitter truth behind cough syrup scare

Bottled negligence: DEG contamination exposes gaps in inspections, leaving pharma units from Gujarat to Kerala under the microscope

Eli Lilly to invest over $1 billion in India to boost manufacturing

Eli Lilly, which launched its obesity drug Mounjaro in India earlier this year, plans to invest $1 billion to strengthen manufacturing partnerships and set up a new Hyderabad facility

Pharma firms get one-month extension to submit declarations under UCPMP

The Department of Pharmaceuticals extends the deadline for pharma companies to file self-declarations, ensuring compliance with the Uniform Code for Pharmaceutical Marketing Practices (UCPMP)

Samsung's PLI journey ends. Will India's production incentive boom hold?

Samsung has completed its PLI cycle, claiming ₹1,000-1,200 crore in FY25. With payouts ending, India must evaluate whether the scheme builds lasting manufacturing ecosystems

Cipla Q1 preview: Net profit may jump up to 4%, revenue by 8% YoY

Cipla is scheduled to announce its April-June quarter earnings for the financial year 2025-26 (Q1FY26) on Friday, July 25, 2025

Here's what brokerages expect from Dr Reddy's Labs ahead of Q1 show

Dr Reddy's Labs Q1 preview: The company's net profit is expected to come at ₹1,460 crore, marking around 4.9 per cent Y-o-Y increase, on average, as against ₹1,392.4 crore in Q1 FY25

China's biotech surge shifts global drug innovation, stirs US tension

Top regulators like the US FDA and EMA are fast-tracking more Chinese drugs, granting priority review and breakthrough designations as they gain confidence in China's biotech innovation

Anthem Biosciences expands manufacturing capacity ahead of ₹3,395-cr IPO

CRDMO firm Anthem Biosciences expands peptide and API production, with Unit 4 under development, as it prepares for a Rs 3,395-crore IPO opening on July 14

Biocon's ₹4,500 crore equity raise to reduce debt by FY26, says S&P

S&P says Biocon will bring down adjusted debt to Rs 20,000 crore by FY26 through equity issuance, with strong cash flows aiding deleveraging and future capex needs

Rekha Jhunjhunwala portfolio stock soars 17%; zooms over 950% in 2 years

Shares of Wockhardt hit an all-time high of ₹1,809.95, as they rallied 17% on the BSE in Wednesday's intra-day trade surpassed its previous high of ₹1,678.60 touched on February 6, 2025.

US govt order to have nil impact on Indian pharma players, says Cipla

The US government's order to pharma firms to lower the cost of prescription medicines within 30 days will not impact Indian generic drugmakers, Cipla MD and Global CEO Umang Vohra said on Tuesday. He noted that the Executive Order signed by US President Donald Trump on Monday is probably going to impact branded drugs. "What we understand is that this is largely targeted towards branded drugs...As of now, what we understand is that this is a voluntary measure that perhaps the companies will be taking," Vohra stated. He noted that there are aspects of MFN clauses etc and it is not clear as of now how and in which manner the Executive Order will be implemented. "So as of now, from a generic perspective, I think generic (drug) prices in the US are already significantly comparable with the rest of the world, in some cases it is lower. So we don't believe that at least for now, based on what the promulgation says we think this is more (towards) branded sector...rather anything on the ...

Trump vows to slash US drug prices: Why do Americans pay more for pharma?

Unlike most developed nations, the United States lacks a centralised price control system. Instead, prices are set by pharmaceutical firms and negotiated by insurers

CDSCO asks MSME pharma firms to apply online for Schedule M extension

This comes after the health ministry had on February 11 formally extended the deadline for implementing the revised Schedule M by one year for pharma companies with an annual turnover below Rs 250 cr

US tariffs to hit pharma sector, while auto industry impact remains minimal

Enhanced tariffs on pharma imports in the US can severely impact Indian drug manufacturers as it would lead to higher production costs, making shipments less competitive against products from other countries. Smaller drug firms operating on thin margins can face severe pressure potentially forcing consolidation or closure. The automobile sector, on the other hand, is expected to have a very minimal impact owing to the US being a small export market. Terming India as a very high tariff nation, US President Donald Trump has said that reciprocal tariffs on countries that impose levies on American goods will kick in on April 2. India currently levies around 10 per cent import duty on American drugs, while the US doesn't charge any import duty on Indian drugs. Shardul Amarchand Mangaldas & Co Partner Arvind Sharma said as of recent history, the US has been a net importer of pharmaceutical products to meet its domestic demand. "In the event the US decides to impose substantial tariffs

NPPA fixes retail prices of 53 drug formulations, including painkillers

The regulatory body, which comes under the Department of Pharmaceuticals (DoP), took the decision to revise the prices of the formulations during the authority's 130th meeting on February 25

Pfizer may move outside manufacturing plants to US: CEO amid tariff threats

The US president has imposed a 10 per cent tariff across all Chinese imports into the US and proposed a 25 per cent levy on most goods from Mexico and Canada

Piramal Enterprises hit with nearly $172 million tax bill for pharma deal

Maharashtra's tax office has contended that the transfer of its pharma business to Piramal Pharma counts as an itemized sale and not a slump sale, the company said

India pharma exports surge 9%, outpacing global average, says report

India has also surpassed the US in the number of FDA-registered generic manufacturing sites